Compare Carvana Co (CVNA) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Novavax Inc — how do they compare? Carvana Co trades at $63.73 (market cap $69.55B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Carvana Co is far larger — about 38.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Novavax Inc for 59 Days on average.
| CVNA | NVAX | |
|---|---|---|
Market Cap | $69.55B | $1.82B |
Volume | 7,671,750 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $12.75 |
52-Week Low | $56.27 | $6.22 |
Typical Hold Time | 28 Days | 59 Days |
Enterprise Value | $72.04B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $63.21, up 0.72% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 revenue up 52% and net income of $1.41 billion in 2025. Analyst sentiment is divided, with a consensus price target of $84.07, but technical indicators suggest near-term resistance at $64.
The outlook for CVNA hinges on sustained revenue growth and margin expansion, supported by operational improvements and capacity expansions. Key risks include high debt levels, competitive pressures, and sensitivity to interest rates. Upside potential exists if the company continues to exceed earnings expectations and expand its market share in the online used car sector.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
